Medical treatment of bladder cell carcinoma

Progres en Urologie

Volumn 23, Issue 15, 2013, Pages 1238-1245

  Guy, L ^a,b   Mahammedi, H ^c   Bastide, C ^d,e   Bruyere, F ^f,g   Karsenty, G ^d,h   Bay, J O ^a,i  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b Service d'Urologie   (France)

^c CENTRE JEAN PERRIN   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e Polyclinique de Bourgogne   (France)

^f UNIVERSITÉ DE TOURS   (France)

^g CHU BRETONNEAU   (France)

^h HÔPITAL DE LA CONCEPTION   (France)

ⁱ HÔpital Estaing   (France)

Author keywords

BCG; Bladder cancer; Bladder instillations; Chemotherapy; Diagnosis

Indexed keywords

5-AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BCG VACCINE; CISPLATIN; DEOXYCYTIDINE; DIAGNOSTIC AGENT; DOXORUBICIN; DRUG DERIVATIVE; GEMCITABINE; METHOTREXATE; MITOMYCIN; PHOTOSENSITIZING AGENT; VINBLASTINE; VINFLUNINE;

BLADDER CANCER; BLADDER INSTILLATIONS; BLADDER TUMOR; CANCER DE LA VESSIE; CARCINOMA; CHEMOTHERAPY; CHIMIOTHÉRAPIE; CYSTOSCOPY; DIAGNOSIS; DIAGNOSTIC; FLUORESCENCE; HUMAN; INSTILLATIONS ENDOVÉSICALES; MYCOBACTERIUM BOVIS BCG; REVIEW;

BCG; BLADDER CANCER; BLADDER INSTILLATIONS; CANCER DE LA VESSIE; CHEMOTHERAPY; CHIMIOTHÉRAPIE; DIAGNOSIS; DIAGNOSTIC; INSTILLATIONS ENDOVÉSICALES;

AMINOLEVULINIC ACID; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; CARCINOMA; CISPLATIN; CYSTOSCOPY; DEOXYCYTIDINE; DOXORUBICIN; FLUORESCENCE; HUMANS; METHOTREXATE; MITOMYCIN; PHOTOSENSITIZING AGENTS; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84886953690     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2013.09.015     Document Type: Short Survey

References (39)

1. http://www.invs.sante.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-chroniques-et-traumatismes/2011/Projection-de-l-incidence-et-de-la-mortalite-par-cancer-en-France-en-2011.
2. http://www.atih.sante.fr/.
3. http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-4100_hexvix_.pdf.
4. Jichlinski P., Guillou L., Karlsen S.J., Malmström P.U., Jocham D., Brennhovd B., et al. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for the photodiagnosis of superficial bladder cancer: a multicentre study. J Urol 2003, 170:226-229.
5. Schmidbauer J., Witjes F., Schmeller N., Donat R., Susani M., Marberger M. Improved detection of urothelial carcinoma in situ with Hexaminolevulinate fluorescence cystoscopy. J Urol 2004, 171:135-138.
6. Jocham D., Witjes F., Wagner S., Zeylemaker B., van Moorselaar J., Grimm M.O., et al. Improved detection and treatment of bladder cancer using Hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005, 174:862-866.
7. http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-04/hexvix_29022012_avis_ct11859.pdf.
8. Pfister C., Roupret M., Wallerand H., Davin J.L., Quintens H., Guy L., et al. Recommandations en onco-urologie 2010: tumeurs urothéliales. Prog Urol 2010, 20(Suppl.4):S255-S274.
9. ® des tumeurs urothéliales de vessie: résultats après quatre ans d'évaluation prospective monocentrique. Prog Urol 2013, 23:195-202.
10. http://www.invs.sante.fr/.
11. Saint F., Patard J.J., Salomon L., Alamé W., Cicco A., Abbou C.C., et al. Mécanismes d'action du BCG: vers une approche thérapeutique individualisée (ATI)?. Prog Urol 2000, 10:1118-1126.
12. http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-10/immucyst_-_ct-8219.pdf.
13. http://www.has-sante.fr/portail/upload/docs/application/pdf/ct032504.pdf.
14. Bohle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guérin versus Mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003, 169:90-95.
15. Bohle A., Bock P.R. Intravesical bacillus Calmette-Guérin versus Mitomycin C for superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology 2004, 63:682-687.
16. Shelley M.D., Wilt T.J., Court J., Coles B., Kynaston H., Mason M.D. Intravesical bacillus Calmette-Guérin is superior to Mitomycin C in reducing tumour recurrence in high risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004, 93:485-490.
17. Lamm D.L. Efficacy and safety of bacille Calmette-Guérin immunotherappy in superficial bladder cancer. Clin Infect Dis 2000, 31(Suppl.3):S86-S90.
18. Martinez-Pineiro J.A., Martinez-Pineiro L. BCG update: intravesical therapy. Eur Urol 1997, 31(Suppl.1):31-41.
19. Lamm D.L., van der Meijden A.P., Morales A., Brosman S.A., Catalona W.J., Herr H.W., et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 1992, 147:596-600.
20. Saint F., Irani J., Salomon L., Debois H., Abbou C.C., Chopin D. Étude de la tolérance et de l'efficacité des instillations endovésicales de Bacille Calmette-Guérin dans le traitement prophylactique des tumeurs superficielles de vessie, en utilisant un traitement d'entretien. Prog Urol 2001, 11:647-656.
21. Colombel M., Saint F., Chopin D., Malavaud B., Nicolas L., Rischmann P. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006, 176:935-939.
22. http://www.has-sante.fr/portail/upload/docs/application/pdf/ct020867.pdf.
23. http://www.has-sante.fr/portail/upload/docs/application/pdf/ct032469.pdf.
24. http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/ametycine_-_ct-_8424.pdf.
25. Sternberg C.N., Yagoda A., Scher H.I., Watson R.C., Ahmed T., Weiselberg L.R., et al. Preliminaryresults of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitionalcellcarcinoma of the urothelium. J Urol 1985, 133:403-407.
26. Bamias A., Tikiakos I., Karali M.D., Dimopoulos M.A. Systemic chemotherapy in inoperable or metastaticbladder cancer. Ann Oncol 2006, 17:553-561.
27. Rosenberg J.E., Cerroll P.R., Small E.J. Update on chemotherapy for advanced bladder cancer. J Urol 2005, 174:14-20.
28. Garcia J.A., Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol 2006, 24:5545-5551.
29. Radhavan D., Shipley W.U., Garnick M.B., Russell P.J., Richie J.P. Biology and management of bladder cancer. N Engl J Med 1990, 322:1129-1138.
30. Sternberg C.N., de Mulder P.H., Schornagel J.H., Théodore C., Fossa S.D., van Oosterom A.T., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic M-VAC in advancedurothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No.30924. J Clin Oncol 2001, 19:2638-2646.
31. Sternberg C.N., de Mulder P., Schornagel J.H., Theodore C., Fossa S.D., van Oosterom A.T., et al. Seven-year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006, 42:50-54.
32. Vogelzang N.J. Future directions for gemcitabine in the treatment of genitourinary cancer. Semin Oncol 2002, 29(Suppl.3):40-45.
33. Sternberg C.N. Gemcitabine in bladder cancer. Semin Oncol 2000, 27(Suppl.2):31-39.
34. von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev AnticancerTher 2003, 3:11-19.
35. Pollera C.F., Ceribelli A., Crecco M., Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase 1study. Ann Oncol 1994, 5:182-184.
36. von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005, 23:4602-4608.
37. Stadler W.M., Kuzel T., Roth B., Raghavan D., Dorr F.A. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997, 15:3394-3398.
38. von der Maase H., Hansen S.W., Roberts J.T., Dogliotti L., Oliver T., Moore M.J., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18(17):3068-3077.
39. http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-01/javlor_-_ct-_7131.pdf.